Comparative Pharmacology
Head-to-head clinical analysis: CYCRIN versus NORETHINDRONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCRIN versus NORETHINDRONE ACETATE.
CYCRIN vs NORETHINDRONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Medroxyprogesterone acetate is a progestin that inhibits gonadotropin secretion, suppressing ovulation and inducing a withdrawal bleeding in an estrogen-primed endometrium. It exerts its effects via binding to progesterone receptors, leading to endometrial transformation and inhibition of endometrial proliferation.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial thinning. Also binds to progesterone receptors, exerting antiestrogenic effects.
2.5 mg to 10 mg orally once daily for 5 to 10 days per cycle.
Oral, 5 mg once daily for 14 days per cycle, beginning on day 1 of menstrual cycle; for endometriosis, 5 mg daily for 14 days then 10 mg daily for 14 days, then 15 mg daily, or as tolerated up to 15 mg daily continuous.
None Documented
None Documented
Terminal elimination half-life ranges from 12 to 24 hours, supporting once-daily dosing for continuous hormone replacement.
Terminal elimination half-life is approximately 5-8 hours (mean 7.5 hours). Clinically, steady-state is achieved within 2-3 days of daily dosing.
Primarily renal (50-60% as sulfate and glucuronide conjugates), with approximately 30% fecal elimination.
Renal (39-61% as metabolites), biliary/fecal (35-49% as metabolites). Less than 1% excreted unchanged.
Category C
Category D/X
Progestin
Progestin